Company / Current Assets
Spyre Therapeutics, Inc. Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$777.8M
FY2025
5-year range
$62.3M / $777.8M
FY2021-FY2025
Trend
+27.8%
vs FY2024
Sector context
#73 of 213
Health Care
What the data says
At $778M, Spyre Therapeutics, Inc.'s current assets ranks #73 of 213 in the Health Care sector. Current Assets has increased for 3 consecutive years, from $62M in FY2022 to $778M in FY2025.
Based on SEC 10-K filings.
$778M in FY2025 with a 5-year CAGR of +39.0%.
Improved from $342M to $778M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- +132.0%
- 5-Year CAGR
- +39.0%
- 10-Year CAGR
- -
Sector benchmark
#73 of 213 in Health CareTop 34% of 213This company $777.8M Sector average $2.5B
▼
-69.2% below sector average
Key checks
Key Insights
- Spyre Therapeutics, Inc.'s current assets has grown for 3 consecutive years.
- 5-year CAGR of +39.0%, indicating consistent growth.
- In FY2025, current assets increased 27.8% year-over-year.
- Ranks #73 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $777.8M | +27.8% |
| FY2024 | $608.5M | +78.2% |
| FY2023 | $341.5M | +448.6% |
| FY2022 | $62.3M | -37.0% |
| FY2021 | $98.9M | -34.0% |
| FY2020 | $149.8M | +101.0% |
| FY2019 | $74.5M | -2.8% |
| FY2018 | $76.7M | +39.4% |
| FY2017 | $55.0M | -17.2% |
| FY2016 | $66.4M | +73.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026